Surprise data! A breakthrough has been made in the new first-line treatment regimen, and the survival of patients with advanced esophageal cancer has been prolonged
At the European Society for Medical Oncology (ESMO) meeting in Madrid, the esophageal cancer team of our hospital presented the results of a single-arm multicenter phase II clinical study called "Anlotinib in combination with TQB2450 first-line treatment of advanced esophageal squamous cell carcinoma", which made a major breakthrough in progression-free survival and showed the great potential of "anti-angiogenic + immune" regimen in the first-line treatment of advanced esophageal cancer. The results of the study showed that among all patients, 1 had a complete response, 31 had a partial response, 11 had a stable condition, and 3 had no effect. The preliminary overall response rate (ORR) was 69.6%, the disease control rate (DCR) was 93.5%, and the median PFS was 9.92 months. Compared with the standard "chemotherapy + immunization" regimen, the ORR and DCR data in this study were comparable, but the median PFS reached 12 months, and the 12-month OS rate was 70.71%. In addition, the incidence ≥of toxicity and side effects related to grade 3 treatment was only 22%, which greatly reduced the toxicity of treatment and improved the tolerability and completion of treatment for patients. This study is expected to comprehensively improve the survival benefit of patients with first-line treatment of advanced esophageal cancer, showing broad prospects.
